Johnson and Johnson has recently said they will be taking complete charge of the vaccine production post the unfortunate incident that had occurred at the Baltimore plant, which resulted in the lost of nearly 15 million doses of vaccine.
Production at the Baltimore factory of the vaccine that was originally formulated by AstraZeneca will be relocated to someplace else, with assistance from the Biden Administration, especially due to the conflation of ingredients that had actually caused the fiasco.
Johnson And Johnson Claims To Take Complete Charge Of Vaccine Manufacturing At The Baltimore Plant
This decision was followed by the news that was circulating recently, where Johnson and Johnson had lost an entire batch of doses totaling to nearly 15 million doses, at their plant based in Baltimore. Reportedly, this blunder was caused due to some “human error”, where an employee had accidentally mixed up the ingredients of Johnson and Johnson with that of AstraZeneca.
However, while addressing this unfortunate blunder, Johnson and Johnson assured that the situation does not call for much concern, since the problem was immediately detected through routine quality checks. Additionally, all the doses that have been shipped out to the U.S. have come from a plant at Netherlands, not Baltimore. AstraZeneca, at that moment, had declined to comment on this matter.
The Baltimore plant is run by Emergent Biosolutions, a leading biopharmaceutical giant headquartered in Maryland. Following the incident, a senior federal health official had suggested that only one vaccine should be made at the site, so as to prevent any further accidents like this.
In a recent statement, Johnson and Johnson has confessed to taking “full responsibility” regarding the production of vaccines at the site. Additionally, they have also said that they will sending extra staff to the location to supervise the production process.
On the contrary, AstraZeneca revealed in a statement, that it was seeking the government’s assistance in finding a replacement for the location, for manufacturing its vaccine. However, U.S. officials have not authorized any location yet.
Johnson and Johnson had said that they plan on producing 100 million doses by June and even aim at delivering earlier, by May. If this does happen, President Biden’s wish of immunizing the entire adult population by May will be fulfilled.
Nina Delorenzo, who serves as the Vice President of Emergent Biosolutions, had said that the company had been informed about the decision regarding the relocation of the AstraZeneca’s manufacturing process. Naturally, Emergent plans on stopping the production of AstraZeneca’s vaccine from the next few days. Lorenzo has additionally mentioned that they are welcoming extra personnel at the Baltimore for their technical support.
The plant at Baltimore is not yet authorized by U.S. regulators to produce vaccines and sell them to the consumers. Furthermore, this recent incident is causing the authorization to get delayed as the FDA continues to inspect what happened. For now, the ruined batch has been isolated will accordingly be, discarded.
Upon thorough investigation, it has been revealed that an inspector from FDA had reported several problems he had found at the Baltimore plant, in April last year. Despite those problems, the Trump Administration had secured a deal with Emergent Biosolutions for $628 million, as a result of Operation Warp Speed, a government initiative to accelerate the production of Covid-19 vaccines. Not only that but, the company also signed deals amounting over $740 million with Johnson & Johnson as well as AstraZeneca, to manufacture Covid-19 vaccines for both the drug companies at the Baltimore factory.
Hopefully, the decision for relocation made by AstraZeneca will restrict further accidents from happening.